Data monitoring committees and interim monitoring guidelines.
about
Role of the Data and Safety Monitoring Committee (DSMC).Reported use of data monitoring committees in the main published reports of randomized controlled trials: a cross-sectional study.Systematic qualitative review of the literature on data monitoring committees for randomized controlled trials.Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.The value of randomized clinical trials in ophthalmology.Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCA sequential conditional probability ratio test procedure for comparing diagnostic tests.Can we trust the results of trials that are stopped early?The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trialThree-component cure rate model for nonproportional hazards alternative in the design of randomized clinical trials.Monitoring for lack of benefit: a critical component of a randomized clinical trialStatistical challenges in the evaluation of treatments for small patient populations.Comparison of futility monitoring guidelines using completed phase III oncology trials.Information time scales for interim analyses of randomized clinical trials.Safety and efficacy of intensive intraoperative glycaemic control in cardiopulmonary bypass surgery: a randomised trial.Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements.Clinical utility of PET/CT in the evaluation of head and neck squamous cell carcinoma with an unknown primary: a prospective clinical trial.A general formulation for a one-sided group sequential design
P2860
Q30731720-AF0CC9E8-B72E-467F-8D5D-9F6B767CCF8CQ31017555-A4D9B143-197A-4D50-8B92-152566276A6CQ31017562-3E7E4471-C7B4-47BA-B773-DAE202A37B20Q34041573-36C55A2E-134C-4868-947E-BFDCD390BD9AQ34049260-1DBEDEFD-67B7-4491-9899-8605EE8767F9Q34069811-AAF83541-0841-4D81-A300-CCEE7497D9C9Q34310859-EBAA4437-DA41-461D-83D8-75A54AE4BF42Q34414177-3E8F55F5-E26B-4204-961A-328D36E8292CQ34777979-B6057B3E-7F70-46F1-B5E2-4375F60A587BQ35847455-617B35D2-31A6-49D2-98F7-45C97EA4D631Q35902788-81897F6A-CB70-477A-AA22-136A4E2714CDQ36530313-AE194407-C277-4AE2-8A86-34CD8D443A25Q36734547-D40AD804-2A67-4DCB-AE00-08483CD58CABQ37000193-E8F4C197-E0CC-417B-AFB3-A6B384838B47Q37104771-05AD148E-D301-4882-9448-12B599406BC9Q38093778-98ED16F2-2174-4600-919F-590981A1E400Q39427133-BDEB360F-E2AE-45ED-A9E2-FBB53B1AF75CQ39802570-5D786C21-A045-494C-AC03-005CBA5DEE9CQ47899293-5A355582-CDF3-4871-B512-63FA0BD24440Q52690719-C54B567F-BF1A-496E-A679-15381782267EQ53219329-0EDCB223-DCA9-460E-994F-A2B56A14491BQ56906172-B30FFD71-2334-4ADB-9246-00DEE2755196
P2860
Data monitoring committees and interim monitoring guidelines.
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Data monitoring committees and interim monitoring guidelines.
@ast
Data monitoring committees and interim monitoring guidelines.
@en
type
label
Data monitoring committees and interim monitoring guidelines.
@ast
Data monitoring committees and interim monitoring guidelines.
@en
prefLabel
Data monitoring committees and interim monitoring guidelines.
@ast
Data monitoring committees and interim monitoring guidelines.
@en
P2093
P1476
Data monitoring committees and interim monitoring guidelines.
@en
P2093
P304
P356
10.1016/S0197-2456(99)00017-3
P407
P577
1999-10-01T00:00:00Z